FOCUS ISSUE: PLAQUE NEOVASCULARIZATION, HEMORRHAGE, AND VULNERABILITY: STATE-OF-THE-ART PAPER
Plaque Neovascularization and Antiangiogenic Therapy for Atherosclerosis
Brendan Doyle, MD* and
Noel Caplice, MD, PhD ,*
* Division of Cardiovascular Diseases, Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota
Centre for Research in Vascular Biology, Biosciences Institute, University College Cork, Cork, Ireland
Manuscript received May 24, 2006;
revised manuscript received December 12, 2006,
accepted January 18, 2007.
* Reprint requests and correspondence: Dr. Noel Caplice, Centre for Research in Vascular Biology, Biosciences Institute, University College Cork, Co. Cork, Ireland. (Email: n.caplice{at}ucc.ie).
The concept that neovascularization of the vessel wall may play a fundamental role in the pathophysiology of atherosclerosis was proposed more than a century ago. In recent years, supportive experimental evidence for this hypothesis (such as the finding that neointimal microvessels may increase delivery of cellular and soluble lesion components to the vessel wall) has been underscored by clinical studies associating plaque angiogenesis with more rapidly progressive high-grade disease. Attention has also focused on a possible role for microvessel-derived intraplaque hemorrhage in the development of acute lesion instability. The interest of clinicians in this phenomenon has been spurred by the potential to target vessel wall neovascularization with angiogenesis inhibitors, a therapeutic approach that has been associated with impressive reductions in plaque progression in animal models of vascular disease. The rationale for pursuing an "antiangiogenic" strategy in the treatment of patients with vascular disease, and a framework for further preclinical evaluation of such therapy, is presented here.
|
Abbreviations and Acronyms
| | HIF = hypoxia inducible factor | | VEGF = vascular endothelial growth factor |
|
This article has been cited by other articles:
|
|
|
|
 
D. Nam, C.-W. Ni, A. Rezvan, J. Suo, K. Budzyn, A. Llanos, D. Harrison, D. Giddens, and H. Jo
Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis
Am J Physiol Heart Circ Physiol,
October 1, 2009;
297(4):
H1535 - H1543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe, G. Leung, N. R. Munce, A. S. Thind, H. Leong-Poi, K. J.T. Anderson, X. Qi, J. Trogadis, A. Nadler, D. Shiff, et al.
Natural History of Experimental Arterial Chronic Total Occlusions.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1148 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Magnoni, S. Coli, M. M. Marrocco-Trischitta, G. Melisurgo, D. De Dominicis, D. Cianflone, R. Chiesa, S. B. Feinstein, and A. Maseri
Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries
Eur J Echocardiogr,
March 1, 2009;
10(2):
260 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Winter, S. D. Caruthers, H. Zhang, T. A. Williams, S. A. Wickline, and G. M. Lanza
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
J. Am. Coll. Cardiol. Img.,
September 1, 2008;
1(5):
624 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Folts
Arterial Blood Pressure Gradient Across Vulnerable Plaque Might Increase Rupture
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2440 - 2440.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Doyle and N. Caplice
Reply
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2440 - 2440.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Ritman and A. Lerman
The dynamic vasa vasorum
Cardiovasc Res,
September 1, 2007;
75(4):
649 - 658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Herrmann and A. Lerman
Atherosclerosis in the Back Yard
J. Am. Coll. Cardiol.,
May 29, 2007;
49(21):
2102 - 2104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
